plasma concentration and adverse effects.estrogens esterifiedestrogens esterified, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic antidepressants. However, interactions are not common.estropipateestropipate, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.ethanolethanol, amitriptyline. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive impairment of motor skills.ethinylestradiolethinylestradiol, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.etomidateetomidate, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.etravirineetravirine will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.eucalyptusamitriptyline and eucalyptus both increase sedation. Minor/Significance Unknown.chlordiazepoxide and eucalyptus both increase sedation. Minor/Significance Unknown.felodipinefelodipine will increase the level or effect of amitriptyline by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.fleroxacinfleroxacin increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.fluconazolefluconazole increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.fludrocortisonefludrocortisone will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.fluphenazineamitriptyline, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amitriptyline, fluphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.gemifloxacingemifloxacin increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.glimepirideamitriptyline increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.glipizideamitriptyline increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.glyburideamitriptyline increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.green teagreen tea decreases effects of chlordiazepoxide by pharmacodynamic antagonism. Minor/Significance Unknown. Caffeine component of green tea may decrease sedative effects of benzodiazepines.griseofulvingriseofulvin will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.hydrocortisonehydrocortisone will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.hydroxyprogesterone caproate (DSC)hydroxyprogesterone caproate (DSC), amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.insulin aspartamitriptyline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.insulin detemiramitriptyline increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.insulin glargineamitriptyline increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.insulin glulisineamitriptyline increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.insulin lisproamitriptyline increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.insulin NPHamitriptyline increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.insulin regular humanamitriptyline increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.isoniazidisoniazid will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.isoproterenolisoproterenol, amitriptyline. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.itraconazoleitraconazole will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ketamineketamine, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.ketoconazoleketoconazole increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.lapatiniblapatinib will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.larotrectiniblarotrectinib will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.levofloxacinlevofloxacin increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.levoketoconazolelevoketoconazole increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.lithiumlithium, amitriptyline. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.lumefantrinelumefantrine will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.marijuanamarijuana will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.mestranolmestranol, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.metforminamitriptyline increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.methylprednisolonemethylprednisolone will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.metronidazolemetronidazole will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.metyraponeamitriptyline decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.chlordiazepoxide decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.miconazole vaginalmiconazole vaginal will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.miconazole vaginal increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.miglitolamitriptyline increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.moxifloxacinmoxifloxacin increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.nateglinideamitriptyline increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.nevirapinenevirapine will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.nifedipinenifedipine will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.nilotinibnilotinib will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ofloxacinofloxacin increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.omeprazoleomeprazole increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.oxcarbazepineoxcarbazepine will increase the level or effect of amitriptyline by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.oxcarbazepine will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.panax ginsengpanax ginseng increases effects of amitriptyline by pharmacodynamic synergism. Minor/Significance Unknown.parecoxibparecoxib will increase the level or effect of amitriptyline by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.pentobarbitalpentobarbital, amitriptyline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.perphenazineamitriptyline, perphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amitriptyline, perphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.phenobarbitalphenobarbital, amitriptyline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.pioglitazoneamitriptyline increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.pleurisy rootpleurisy root decreases effects of amitriptyline by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.posaconazoleposaconazole will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.posaconazole increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.prednisoneprednisone will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.rifabutinrifabutin decreases levels of chlordiazepoxide by increasing metabolism. Minor/Significance Unknown.primidoneprimidone, amitriptyline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.prochlorperazineamitriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amitriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.progesterone micronizedprogesterone micronized, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.promazineamitriptyline, promazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amitriptyline, promazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.promethazineamitriptyline, promethazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amitriptyline, promethazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.propofolpropofol, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.quinupristin/dalfopristinquinupristin/dalfopristin will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.repaglinideamitriptyline increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.rifampinrifampin decreases levels of chlordiazepoxide by increasing metabolism. Minor/Significance Unknown.rosiglitazoneamitriptyline increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.rufinamiderufinamide will decrease the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.sagechlordiazepoxide and sage both increase sedation. Minor/Significance Unknown.amitriptyline and sage both increase sedation. Minor/Significance Unknown.saxagliptinamitriptyline increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.vinpocetinechlordiazepoxide increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).secobarbitalsecobarbital, amitriptyline. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.serdexmethylphenidate/dexmethylphenidateserdexmethylphenidate/dexmethylphenidate increases effects of amitriptyline by decreasing metabolism. Minor/Significance Unknown.sevofluranesevoflurane, amitriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.sitagliptinamitriptyline increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.sulfamethoxazolesulfamethoxazole decreases levels of amitriptyline by unspecified interaction mechanism. Minor/Significance Unknown.thioridazineamitriptyline, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amitriptyline, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.tolazamideamitriptyline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.tolbutamideamitriptyline increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.trifluoperazineamitriptyline, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.amitriptyline, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.vasopressinamitriptyline increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.verapamilverapamil will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.verapamil increases levels of amitriptyline by decreasing metabolism. Minor/Significance Unknown.vildagliptinamitriptyline increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.voriconazolevoriconazole increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown.voriconazole will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.zafirlukastzafirlukast will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.zolpidemzolpidem, chlordiazepoxide. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.5-HTPMonitor Closely (1)amitriptyline and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.abametapirSerious - Use Alternative (1)abametapir will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.abirateroneMonitor Closely (2)abiraterone increases levels of amitriptyline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate. abiraterone increases levels of chlordiazepoxide by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.abobotulinumtoxinAMonitor Closely (1)abobotulinumtoxinA increases effects of amitriptyline by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .acarboseMinor (1)amitriptyline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.acetazolamideMinor (1)acetazolamide will increase the level or effect of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.aclidiniumMonitor Closely (1)aclidinium and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.acrivastineMonitor Closely (2)acrivastine and amitriptyline both increase sedation. Use Caution/Monitor. acrivastine and chlordiazepoxide both increase sedation. Use Caution/Monitor.adagrasibSerious - Use Alternative (1)adagrasib, amitriptyline. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.albuterolMonitor Closely (3)albuterol and amitriptyline both increase QTc interval. Use Caution/Monitor. chlordiazepoxide increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. amitriptyline increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)amitriptyline, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.alfentanilMonitor Closely (2)alfentanil and amitriptyline both increase sedation. Use Caution/Monitor. chlordiazepoxide and alfentanil both increase sedation. Use Caution/Monitor.alfuzosinMonitor Closely (2)amitriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and amitriptyline both increase QTc interval. Use Caution/Monitor.almotriptanMonitor Closely (1)almotriptan and amitriptyline both increase serotonin levels. Modify Therapy/Monitor Closely.alprazolamMonitor Closely (2)alprazolam and chlordiazepoxide both increase sedation. Use Caution/Monitor. alprazolam and amitriptyline both increase sedation. Use Caution/Monitor.amifampridineMonitor Closely (1)amitriptyline increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.amiodaroneMonitor Closely (1)amiodarone will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.Serious - Use Alternative (1)amitriptyline and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.amisulprideMonitor Closely (4)amitriptyline and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered. amisulpride and amitriptyline both increase sedation. Use Caution/Monitor. amisulpride and amitriptyline both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered. amisulpride and chlordiazepoxide both increase sedation. Use Caution/Monitor.amitriptylineMonitor Closely (1)chlordiazepoxide and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalMonitor Closely (6)amobarbital and amitriptyline both